Amphetamine enhances recovery after experimental ischaemia and has shown promise in small clinical trials when combined with motor or sensory stimulation. Amphetamine, a sympathomimetic, might have haemodynamic effects in stroke patients, although limited data have been published. Subjects were recruited 3-30 days post-ischaemic stroke into a phase II randomized (1:1), double-blind, placebo-controlled trial. Subjects received dexamphetamine (5 mg initially, then 10 mg for 10 subsequent doses with 3-or 4-day separations) or placebo in addition to inpatient physiotherapy. Recovery was assessed by motor scales (Fugl-Meyer (FM)), and functional scales (Barthel index (BI) and modified Rankin score (mRS)). Peripheral blood pressure (BP), central haemodynamics and middle cerebral artery blood flow velocity were assessed before, and 90 min after, the first two doses. Thirty-three subjects were recruited, aged 33-88 (mean 71) years, males 52%, 4-30 (median 15) days post stroke to inclusion. Sixteen patients were randomized to placebo and seventeen to amphetamine. Amphetamine did not improve motor function at 90 days; mean (s.d.) FM 37.6 (27.6) vs control 35.2 (27.8) (P ¼ 0.81). Functional outcome (BI, mRS) did not differ between treatment groups. Peripheral and central systolic BP, and heart rate (HR), were 11.2 mm Hg (P ¼ 0.03), 9.5 mm Hg (P ¼ 0.04) and 7 beats per minute (P ¼ 0.02) higher, respectively, with amphetamine, compared with control. A nonsignificant reduction in myocardial perfusion (BUI) was seen with amphetamine. Other cardiac and cerebral haemodynamics were unaffected. Amphetamine did not improve motor impairment or function after ischaemic stroke but did significantly increase BP and HR without altering cerebral haemodynamics.
Introduction
Modern concepts in stroke recovery now include the brain's capacity to undergo dynamic plastic change. 1 This plasticity is exploited by rehabilitation which is effective at improving outcome, and it might be possible to enhance this recovery further using pharmacological means, 2 an approach that has been referred to as 'pharmacological rehabilitation. 3, 4 In experimental models cerebral ischaemia results in a catecholamine deficit, whereas drugs that negatively regulate central neurotransmitters, such as haloperidol, (a dopamine receptor antagonist), have detrimental affects on outcome in both experimental and clinical stroke. 5, 6 It has been hypothesized that increasing catecholamines could facilitate recovery following stroke, and that centrally acting neurotransmitters might modulate plasticity. 7, 8 Amphetamine, a sympathomimetic drug, has been shown to accelerate the recovery of motor function in experimental models of stroke when given in conjunction with task-specific practice. 5, 9, 10 However, timing and dose of administration appears important; high doses and early administration being associated with a poor outcome, 5, 11 whereas pretreatment with amphetamine led to increased ischaemic insult. 12 The evidence in normal subjects [13] [14] [15] and in clinical stroke is less clear, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] numerous small trials, utilising varying dosage and timing of treatment, showing conflicting results, overall demonstrating no evidence of benefit on motor recovery. Although treatment appears feasible and well tolerated, a trend towards increased death in the treatment group exists on meta-anlaysis. 28 As such, there is currently no evidence to support the routine use of amphetamine.
Despite well-documented systemic effects of amphetamine, 29 in particular its effect of raising blood pressure (BP) and heart rate (HR), limited data exist regarding the effect of amphetamine on peripheral haemodynamics in patients with recent ischaemic stroke. One trial found that amphetamine increased BP and HR in stroke, 30 important as hypertension is a major risk factor for further stroke, 31 and for a poor outcome. 32 Furthermore, no data exist on the effect of amphetamine on central or cerebral haemodynamic in this population, despite recent evidence that these parameters can be related to outcome in acute stroke. 33, 34 We performed a phase II trial assessing the effect of amphetamine on motor function, and cerebral and cardiac haemodynamics. We hypothesized that amphetamine would improve recovery from stroke when given with physiotherapy, and sympathomimetic actions would increase BP and HR, and alter cardiac haemodynamics and cerebral blood flow velocity.
Methods

Design
We performed a prospective, single-centre, doubleblind, randomized placebo-controlled phase II trial of amphetamine in patients with recent ischaemic stroke. A sample size of 42 was required based on an unpublished meta-analysis of four small trials, 16, 17, 19, 25 which showed a beneficial effect of amphetamine on motor impairment assessed as the Fugl-Meyer (FM) motor scale: randomization ratio of 1:1, mean treatment difference 16 
Subjects
Previously independent (modified Rankin score (mRS)o3) adult patients with recent ischaemic stroke (3-30 days postictus) and motor weakness (arm and leg components of Scandinavian Stroke Scale (SSS)o6) were identified and enrolled from Nottingham City Hospital (NCH). Patients were recruited as early as possible after 3 days once they had become clinically stable. The principal exclusion criteria were contraindications to amphetamine, including intracerebral haemorrhage, ischaemic heart disease, uncontrolled hypertension (4160/100 mm Hg), thyrotoxicosis and history of seizures; patients with dementia, coma or pregnancy were also excluded. Full written informed consent was obtained from patients before randomization, or assent taken from a relative/carer if the patient was incompetent, confused or dysphasic.
Intervention
Patients were randomized to receive either amphetamine or placebo using computerized minimization on age, sex, baseline severity (SSS) and baseline Motricity Index (MI) upper extremity score. Dexamphetamine sulphate (initial 5 mg dose followed by 10 mg thereafter) or placebo was administered orally twice a week with alternating 3-or 4-day separations. 17, 23, 24, 26, 35, 36 The dose of 10 mg is unlikely to cause dependency or extreme vascular instability. There were a total of 11 doses covering a treatment period of 35 days. Treatment was given 1-2 h before scheduled physiotherapy.
Outcome measures
The primary outcome was motor impairment as assessed by FM (upper extremity) motor scale at day 90. Secondary outcomes included MI (upper limb), severity (SSS), Barthel index (BI), mRS, extended activity of daily living (EADL), language skills (Sheffield screening test), cognition (mini-mental state examination), mood (Zung depression score) and quality of life (health state test); these were assessed at the end of treatment (day 35) and day 90. Discharge disposition and length of hospital stay were also recorded. Safety was assessed as mortality, serious adverse events (SAE), stroke recurrence (ischaemic or haemorrhagic), acute coronary syndrome (myocardial infarction, unstable angina) and symptomatic cardiac dysrhythmia during the study period.
Haemodynamic measures
Cerebral and cardiac measurements were made immediately before and 90 min after both the first (dexamphetamine 5 mg) and the second treatment (dexamphetamine 10 mg) doses. Peripheral systolic and diastolic BP (SBP, DBP) and HR were measured with a validated digital readout oscillometric device (Omron HEM-705CP, IL, USA). Pulse pressure (PP ¼ SBPÀDBP) and rate-pressure product (RPP ¼ HR Â SBP) were calculated from measured parameters. 37 Central BP, mean arterial pressure (MAP), compliance (augmentation index (AI)) and myocardial perfusion (Buckberg index (BUI) 38 ) were assessed by applanation tonometry pulse wave analysis (SphygmoCor Px, Australia) at the radial artery. Cardiac output and peripheral vascular resistance were measured by Portapres (NO-TPD Biomedical Instrumentation, Amsterdam, Netherlands).
The middle cerebral artery (MCA) was insonnated bilaterally by transcranial Doppler (Nicolet EME Companion, Kleimoftheim, Germany) 39 and systolic flow velocity (SFV), diastolic flow velocity (DFV), mean flow velocity (MFV) and pulsatility index (PI) recorded. Estimated cerebral perfusion pressure (CPP) was calculated using a mean of contralateral and ipsilateral cerebral blood flow velocity as follows: 40, 41 
All clinical measurements were performed blinded to treatment assignment, and outcome measures were performed blinded to haemodynamic measures and treatment. Measurements were not adjusted for concurrent antihypertensive therapy (as with previous studies) because this was very variable depending, in part, on the supervising consultant's medical practice.
Statistical methods
Data are presented as mean (s.d.), median (interquartile range (IQR)) or number (%), and were analysed using Fisher's exact test, Student's t-test, Mann-Whitney U test, or comparison by ANCOVA with adjustment for baseline values, as appropriate. All analyses were performed using SPSS (Apple Patients assigned to amphetamine were more likely to be male than in the placebo group otherwise both groups were matched for age, baseline BP and stroke severity (Table 1) .
Recovery
There was no difference between treatment groups in FM scores (primary outcome) at day 90 (Table 2) . Similarly, there was no difference between groups in the secondary outcome measures of impairment (MI and SSS) or function (BI, mRS and EADL) at day 35 or day 90. Length of stay and discharge disposition did not differ between treatment groups (Table 2) . No differences were observed between the treatment groups in terms of language skills (Sheffield screening test), cognition (mini-mental state examination), mood (Zung depression score) or quality of life (health state test) (data not shown).
Haemodynamic measures
Both groups were well matched for baseline BP (Table 1) , although patients assigned to placebo had a higher HR, whereas patients in the amphetamine group had higher cerebral blood flow velocities. Peripheral and central BP were 11.2/5.8 mm Hg and 9.5/6.6 mm Hg higher, respectively, after amphetamine than placebo (Table 3) . PP was unaffected by amphetamine. HR was significantly increased by 7-9 beats per minute after amphetamine (Table 3) . RPP was increased after amphetamine, with a trend towards a reduction in myocardial perfusion (BUI) present after the second dose of amphetamine (Table 3) . Other cardiac haemodynamics, including vessel compliance, cardiac output and total peripheral resistance were unaffected by amphetamine. Similarly, amphetamine did not significantly alter MCA blood flow velocity or estimates of CPP (Table 3) .
Safety
No patients died during the course of the study, one patient each had a recurrent ischaemic stroke (placebo group) and transient ischaemic attack (placebo group) ( Table 4 ). There were no episodes Amphetamine increases blood pressure not recovery N Sprigg et al of acute coronary syndrome, or symptomatic dysrhythmia or epilepsy. Serious adverse event rates did not differ between treatment groups (four vs three, P ¼ 0.69) ( Table 4) .
Discussion
This phase II trial set out to assess the effect of amphetamine on functional outcome and haemodynamic parameters in patients with recent ischaemic stroke. The primary hypothesis that amphetamine would reduce motor impairment was not supported. Additionally, there were no effects on other measures of impairment, disability, mood and quality of life. Early studies of amphetamine after stroke suggested motor impairment might be reduced, 16, 17, 19 ,25 data we used to power the present trial. However, more recent studies have not supported this finding. Taking all the studies together (including that reported here), a meta-analysis reveals no evidence of efficacy, standardized mean difference (SMD) 0.12 (95% confidence interval (CI), À0.25-0.50) (Figure 2a) .
Amphetamine is known to have powerful effects on BP and HR in normal subjects; indeed, a sympathetic surge resulting in hypertension is well recognized as a cause of stroke when recreational doses of the drug are taken. 42 Unsurprisingly, amphetamine also increased peripheral BP and HR in this study, as has been found in earlier trials in patients with recent stroke. 22, 26 Meta-analysis of these data show that amphetamine increases systolic BP (weighted mean difference) by 9.3 mm Hg (95% CI, 3.3-15.3) (Figure 2b ) and HR by 7.6 beats per minute (95% CI, 1.9-13.4). Amphetamine increases blood pressure not recovery N Sprigg et al
Other haemodynamic parameters are associated with stroke in epidemiological studies, 43 and amphetamine appears to alter some of these. Central BP (rather than peripheral brachial BP) is more relevant to the cerebral circulation and amphetamine increased this. RPP (the mathematical product of HR and systolic BP, 44 an index of myocardial work and associated with a poor outcome after stroke 34 ) was similarly increased with amphetamine. In parallel, the BUI (an estimate of myocardial perfusion) was decreased nonsignificantly after amphetamine. BUI is affected by HR, with tachycardia resulting in shortened diastole and the potential for reduced coronary artery filling. Hence, the positive chronotrophic effect of amphetamine may explain, in part, a tendency for myocardial perfusion to decrease.
Elevation of systemic BP, in the presence of dysfunctional cerebral autoregulation (as occurs in acute ischaemic stroke), might lead to an increase in cerebral blood flow and, potentially, enhance recovery after stroke. 33 However, despite increasing BP, no changes in MCA blood flow velocity or estimated CPP were observed with amphetamine. Changes in cerebral blood flow with amphetamine have been demonstrated previously, 45 although these appeared to be region-specific and, therefore, are probably not detectable using global measures of flow and perfusion (as utilized here).
The lack of effect of amphetamine on recovery may be due to a number of reasons. First, enrolment in this study was terminated early because of a low recruitment rate (a problem seen in other trials with limiting inclusion criteria 24, 46 ), so the intended sample size was not achieved thereby leading to a potential type II error when viewed in the context of the pretrial sample size calculation. This problem was compounded by the heterogeneous nature of recruited patients with widely varying impairment at baseline. Unfortunately, the limited sample size prevents stratification of data by prognostic baseline factors such as stroke syndrome, severity or time to recruitment. Furthermore, to date, no clinical study testing amphetamine in stroke has taken into account ischaemic lesion size or location. 27 Additionally, contemporary care of ischaemic stroke has evolved over the recruitment period of this study, which may also have introduced further heterogeneity. However, the management of BP in acute stroke has not altered during this time. Second, no single outcome measure has been used in the existing amphetamine trials, so the potential for meta-analysis is limited and, again, a type II error may be present. In keeping with this, many of the outcome measures utilized demonstrate ceiling effects, although some studies have excluded patients with mild weakness in an attempt to overcome this. 17, 21, 24, 27 Third, suboptimal dose Amphetamine increases blood pressure not recovery N Sprigg et al regimes might have been tested; the regime utilized here (and pioneered by others 17, 23, 24, 26, 35, 36 ) was driven by concern for potential adverse effects. It is possible that higher and more frequent doses are required, as tested in experimental models. 5, 9, 47, 48 Fourth, treatment was started between 4 and 30 days after stroke onset. Similar studies have failed to address the issue of most favourable time to recruitment and the optimal therapeutic window remains to be elucidated. Finally, perhaps amphetamine has no overall effect on recovery, reflecting a balance between potential benefit and harm. Amphetamine might enhance plasticity, thus reducing impairment, whereas also increasing risk factors for a poor outcome. For example, elevating BP and HR will increase myocardial work load (RPP), as seen here, whereas tachycardia will reduce myocardial perfusion (BUI), a pattern which is likely to promote cardiac events, particularly because many patients with stroke have existing heart disease (whether clinical or occult). Although experimental data supporting the use of amphetamine, whether in animals or normal volunteers, has involved subjects with normal coronary vasculature, 14, 15, 49 a trend towards increased death in stroke patients has been noted previously 28 (although not seen in this study) which supports this hypothesis.
We did not show any benefit of amphetamine therapy on recovery after ischaemic stroke although a moderate treatment effect, whether beneficial or hazardous, cannot be excluded. Amphetamine increased peripheral and central BP, HR, myocardial work rate and tended to reduce myocardial perfusion. In contrast, it had no effect on other central haemodynamic measures or MCA blood flow velocity. Combining these data with those of previous studies, we find no evidence that amphetamine improves motor recovery, perhaps because it induces potentially hazardous effect on systemic haemodynamic parameters. Any future trials of amphetamine should further study its effects on haemodynamic measures.
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